The impact of COVID-19 on clinical research in rare diseases
In our latest whitepaper, The impact of COVID-19 on clinical research in rare diseases, stakeholders can gain insight into the impact that Covid-19 has had across the rare disease sector and the ways in which Orphan Reach have adapted in order to deliver projects successfully throughout a challenging year.
What’s Inside:
- Looking back with you and sharing the challenges faced this year, so that we can come together to deliver on the early indicators of benefits that have also been realised during this toughest of years.
- How new ideas and funding have been impacted during a year of virtual interaction.
- The impact on trial initiations due to reallocation of resources to focus on COVID-19 research across the clinical research sector.
- The effect of the pandemic on trials that were ongoing at the start of 2020 and also the impact on the reporting and approvals for trials that were closed or completed this year. If you have any questions while reading this whitepaper or would like additional information on Orphan Reach’s expertise, feel free to request a consultation.